Author

Bridget Hoag

Genentech

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Aaron LictaoiD· 1 shared Benjamin T. WaltersiD· 1 shared Brett M. BabiniD· 1 shared Caroline L. GilchristiD· 1 shared Elisia VillemureiD· 1 shared Hanna G. BudayevaiD· 1 shared Jean‐Philippe FortiniD· 1 shared Joachim RudolphiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Aaron LictaoORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Rational design of potent small molecule SMARCA2/A4 (BRM/BRG1) degraders acting via the recruitment of FBXO22

Elisia Villemure, Robert L. Yauch, Joachim Rudolph, Tom Januario, Mingshuo Zeng, Hanna G. Budayeva, Benjamin T. Walters, Aaron Lictao, Sherry K. Li, Xiaofen Ye, Caroline L. Gilchrist, Bridget Hoag, Nicholas Endres, Peter Hsu, John Chan, , Joyce Liu

This paper identifies a potent and specific SMARCA2/A4 degrader, G-6599, which works via FBXO22 recruitment and covalent conjugation, offering therapeutic potential.

bioRxiv · Mar 5, 2025 · PreprintCancer Biology